Salmeterol xinafoate - Open Access .click

Results 91 to 100 of about 1,963 (217)

Improved Aerosol Deposition Profiles from Dry Powder Inhalers [PDF]

, 2015
Lung diseases such as asthma and chronic obstructive pulmonary disease (COPD) are major health burdens on the global population. To treat diseases of the lung, topical therapies using dry powder inhalers (DPIs) have been employed.
Parisini, Irene
core +1 more source

Human medicines European public assessment report (EPAR): Airexar Spiromax, salmeterol xinafoate / fluticasone propionate, Pulmonary Disease, Chronic Obstructive,Asthma, Date of authorisation: 18/08/2016, Revision: 2, Status: Withdrawn [PDF]

, 2019
Kernel Networks Inc.
openalex +1 more source

Salmeterol xinafoate in the treatment of mild to moderate asthma in primary care. UK Study Group. [PDF]

, 1994
Kevin Jones
openalex +1 more source

Development and Validation of Stability Indicating HPTLC Method for Estimation of Salmeterol Xinafoate

International Journal of Pharmaceutical Quality Assurance, 2019
A simple, rapid validated stability indicating HPTLC method for estimation of Salmeterol xinafoate was successfully developed. This method is based on HPTLC separation followed by UV detection at 252 nm. The separation was carried out on Merck TLC aluminium sheets precoated with silica gel 60F254 using Chloroform: Methanol: Ammonia (7:3:0.5 v/v/v) as a
Damle M, Choudhari S
openaire +1 more source

Division of Analysis of Homeostasis [PDF]

, 2007
この論文は国立情報学研究所の学術雑誌公開支援事業により電子化されまし
永井博弌
core +1 more source

HPLC method for simultaneous determination of salmeterol xinafoate and fluticasone propionate for the quality control of dry powder inhalation products [PDF]